Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats
In the brain, aminopeptidase A (APA) generates angiotensin III, one of the effector peptides of the brain renin-angiotensin system (RAS), exerting tonic stimulatory control over blood pressure (BP) in hypertensive rats. Oral administration of firibastat, an APA inhibitor prodrug, in hypertensive rat...
Main Authors: | Yannick Marc, Reda Hmazzou, Nadia De Mota, Fabrice Balavoine, Catherine Llorens-Cortes |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332221004649 |
Similar Items
-
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials
by: Sara Abdulrahman Alomar, et al.
Published: (2021-01-01) -
The Discovery of Insulin-Regulated Aminopeptidase (IRAP) Inhibitors: A Literature Review
by: Dimitris Georgiadis, et al.
Published: (2020-09-01) -
Analysis of the antihypertensive drugs prescription on the outpatient level
by: A. Yа. Bazylevych
Published: (2015-10-01) -
Is There an Interplay Between the Functional Domains of IRAP?
by: Anika Vear, et al.
Published: (2020-09-01) -
Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide – which is the better alternative? A meta-analysis
by: Elena Filipova, et al.
Published: (2020-08-01)